Celgene (CELG) Approves Additional $4B Common Buyback

Celgene Corporation (NASDAQ: CELG) today announced that during its June meeting the Company's Board of Directors authorized the repurchase of up to an additional $4.0 billion of the Company's common stock.

This open-ended program is effective immediately. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Celgene's management and in accordance with the requirements of the Securities and Exchange Commission. Celgene now has a total of approximately $5.2 billion remaining from previous authorizations plus the new authorization. Since 2009, Celgene has returned approximately $12.3 billion to shareholders through the repurchase program.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• INmune Bio (INMB) Reports 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
• SPI Energy (SPI) Receives Nasdaq Non-compliance Notice